Screener
Shattuck Labs, Inc. STTK SL-846 — R&D
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Shattuck Labs, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Shattuck Labs, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 6:57 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-055483
| Revenue | Three Months Ended June 30, 2026 / $ | Three Months Ended June 30, 2026 / — | Three Months Ended June 30, 2025 / $ | Three Months Ended June 30, 2025 / — |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development: | ||||
| SL-3251 | 4,107 | 2,604 | ||
| SL-8461 | 1,679 | — | ||
| Other research and development2 | 2,479 | 2,878 | ||
| Research and development non-equity compensation | 2,360 | 2,331 | ||
| Research and development equity compensation | 1,075 | 867 | ||
| Total research and development | 11,700 | 8,680 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is Shattuck Labs, Inc.'s SL-846 — R&D?
- Shattuck Labs, Inc. (STTK) reported SL-846 — R&D of $1.68M in Q2 2026.
- What does SL-846 — R&D mean?
- This metric represents the total direct and allocated operating expenses specifically attributed to the research and development activities of the SL-846 product candidate. It captures the investment intensity required to advance this specific therapeutic program through preclinical or clinical development stages. Monitoring this figure helps investors assess the company's capital allocation strategy and the progress of its pipeline toward potential regulatory milestones.
Ask your AI about Shattuck Labs, Inc.'s sl-846 — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude